TTrialPathMatch Me to Trials
← Back to trials
RecruitingAmpulla of Vater CarcinomaAppendix CarcinomaCarcinoma of Unknown Primary With Gastrointestinal Profile

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

Eligible age

18+ yrs

Accepts

All genders

Locations

38 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This clinical trial is being done to learn whether using the proactive, graduated dose modification algorithm for leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) (PAGODA) algorithm to guide chemotherapy dosing for the FOLFOX regimen works to reduce unplanned treatment delays for patients with digestive system cancers compared to usual care. During standard of care treatment, chemotherapy dose changes or treatment delays are typically determined by the treating physician based on factors such as a patient's height, weight, and blood test results obtained before each treatment cycle. If certain blood counts are too low, the next cycle of chemotherapy may be delayed or adjusted. The PAGODA algorithm is a step-by-step decision-making tool designed to help health care providers determine whether chemotherapy doses should be adjusted or delayed in patients with low neutrophil or platelet counts. Researchers will compare treatment delays, dose changes, and safety outcomes between patients managed using the PAGODA algorithm and patients receiving usual care.

Sponsor: Alliance for Clinical Trials in Oncology

You may qualify if…

  • ✓ \* REGISTRATION ELIGIBILITY CRITERIA (STEP 1)
  • ✓ Histologic confirmation of invasive cancer that is confirmed or suspected to arise from the gastrointestinal (GI) tract
  • ✓ Any stage for which FOLFOX-based chemotherapy is a clinically-indicated, standard-of-care treatment (adjuvant, neoadjuvant, or first-line chemotherapy)
  • ✓ Eligible primary tumor sites include the esophagus, gastroesophageal junction, stomach, small intestine, ampulla of Vater, appendix, colon, rectum, and cancers of unknown primary with suspected GI origin
  • ✓ Prior systemic therapy for GI cancer (other than cycle 1 of FOLFOX-based chemotherapy) is not allowed. Prior radiation-sensitizing chemotherapy is permitted
  • ✓ The planned duration of FOLFOX-based chemotherapy must be at least four cycles (1 cycle = 14 days)
  • ✓ Cycle 1, day 1 of FOLFOX-based chemotherapy must be completed 1 to 8 days prior to registration
  • ✓ Cycle 1, day 1 of FOLFOX-based chemotherapy must include minimum ordered doses of oxaliplatin (≥ 65 mg/m\^2) and infusional 5-FU (2400 mg/m\^2/46 hours). Use of the 5-FU bolus is at the discretion of the treating physician

Where it's recruiting

Alaska

Fairbanks

Arizona

Phoenix

Arkansas

Fort Smith · Jonesboro · Little Rock

California

Arroyo Grande · Carmichael · Elk Grove · Merced …

Colorado

Colorado Springs · Durango · Lakewood · Longmont …

Delaware

Lewes · Millville · Newark · Rehoboth Beach …

Florida

Fort Lauderdale

Georgia

Atlanta · Tifton

Idaho

Boise · Caldwell · Coeur d'Alene · Meridian …

Illinois

Alton · Aurora · Barrington · Bloomington …

Indiana

Crown Point · Dyer · Hobart · Indianapolis …

Iowa

Ames · Ankeny · Boone · Cedar Rapids …

Source: ClinicalTrials.gov · NCT07283939 · last updated 2026-11-04

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent · TrialPath